clinical trial · NCT05038228
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
Pfizer·—·active not recruiting·n = 1
Atrial FibrillationApixabanRivaroxabanDabigatranVitamin K antagonist (VKA)
brief summary
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF with high risk of gastrointestinal bleed who initiate anticoagulant treatment with a Vitamin-K Antagonists (VKAs) or direct-acting oral anticoagulants (DOACs).
started
Aug 1, 2022
primary completion
Apr 8, 2026
completion
Apr 8, 2026
last updated
Mar 12, 2026
official title
Anticoagulant Treatment Patterns and Outcomes Among Non-valvular Atrial Fibrillation Patients With High Risk of Gastrointestinal Bleeding in France: a Retrospective Cohort Analysis Using SNDS Database
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol